Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 6 | 7 | — | — | 15 |
Small cell lung carcinoma | D055752 | — | — | 1 | 6 | 5 | — | — | 12 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Thymoma | D013945 | — | — | — | 1 | — | — | — | 1 |
Thymus neoplasms | D013953 | — | C37 | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Amrubicin |
INN | amrubicin |
Description | Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed.
|
Classification | Small molecule |
Drug class | antineoplastic antibiotics (daunorubicin type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O |
PDB | — |
CAS-ID | 110267-81-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1186894 |
ChEBI ID | — |
PubChem CID | 178149 |
DrugBank | — |
UNII ID | 93N13LB4Z2 (ChemIDplus, GSRS) |